Association of Serum Uric Acid Levels with Components of Metabolic Syndrome: A Cross-Sectional Analysis in a Saudi Adult Population

ORIGINAL ARTICLE
Manal S. Fawzy, Baraah T. Abu AlSel

 
International Journal of Biomedicine. 2020;10(4):457-466.
DOI: 10.21103/Article10(4)_OA25
Originally published December 10, 2020

Abstract: 

Background: This study aimed to investigate the possible relations between serum uric acid (UA) and metabolic syndrome (MetS) and its components in a Saudi adult population sample.
Methods and Results: This cross-sectional study enrolled consecutive adult MetS and non-MetS subjects (90 subjects in each group). Glycemic control indices (fasting blood sugar (FBS), HbA1c, insulin, HOMA-IR index), lipid profile/ratios, and renal function tests were also evaluated.
Findings showed that serum UA was significantly higher in the MetS group (322±98.9) than non-MetS group (286±61.2) μmol/L. The fourth quartile of serum UA showed a higher frequency of MetS (73.3%) and central obesity (82.2%), and higher mean values of TG and FBS as well as lower mean values for HDL-C relative to the first quartiles. Data stratification by sex showed consistent associations of BMI, abdominal obesity, HDL-C, TG/HDL-C, and serum creatinine levels with serum UA in both men and women. Serum UA at 310 μmol/L concentration might be a good predictor for MetS/its components in men. In contrast, at a cut-off level of 275.0 μmol/L, it could significantly predict only obesity and high FBS in women.
Conclusion: Serum UA levels are associated with MetS and may predict MetS and/or its components at specific levels in a sex-dependent pattern in the study population.

Keywords: 
metabolic syndrome • uric acid • lipid profile • insulin resistance • Saudi adults
References: 
  1. Feig DI, Madero M, Jalal DI, Sanchez-Lozada LG, Johnson RJ. Uric acid and the origins of hypertension. J Pediatr. 2013;162(5):896-902. doi:10.1016/j.jpeds.2012.12.078
  2. Neogi T, George J, Rekhraj S, Struthers AD, Choi H, Terkeltaub RA. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum. 2012;64(2):327-338. doi:10.1002/art.33369
  3. Gagliardi AC, Miname MH, Santos RD. Uric acid: A marker of increased cardiovascular risk. Atherosclerosis. 2009;202(1):11-17. doi:10.1016/j.atherosclerosis.2008.05.022
  4. Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?. Curr Hypertens Rep. 2013;15(3):175-181. doi:10.1007/s11906-013-0344-5
  5. Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, Prineas R, Folsom AR, et al. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;108(9):1272-1276. doi:10.1016/j.amjcard.2011.06.043
  6. Liu P, Jiang Y, Meng J. Relationship between serum uric acid, metabolic syndrome and resting heart rate in Chinese elderly. Obes Res Clin Pract. 2016;10(2):159-168. doi:10.1016/j.orcp.2015.04.007
  7. Suzuki I, Yamauchi T, Onuma M, Nozaki S. Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders?. Drugs Today (Barc). 2009;45(5):363-378. doi:10.1358/dot.2009.45.5.1370460
  8. DeBosch BJ, Kluth O, Fujiwara H, Schürmann A, Moley K. Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nat Commun. 2014;5:4642. Published 2014 Aug 7. doi:10.1038/ncomms5642
  9. Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, et al. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies. J Clin Endocrinol Metab. 2015;100(11):4198-4207. doi:10.1210/jc.2015-2527
  10. Fawzy MS, Abu AlSel BT. Assessment of Vitamin D-Binding Protein and Early Prediction of Nephropathy in Type 2 Saudi Diabetic Patients. J Diabetes Res. 2018;2018:8517929. Published 2018 Apr 3. doi:10.1155/2018/8517929
  11. Fawzy MS, Alshammari MA, Alruwaili AA, et al. Factors associated with diabetic foot among type 2 diabetes in Northern area of Saudi Arabia: a descriptive study. BMC Res Notes. 2019;12(1):51. Published 2019 Jan 22. doi:10.1186/s13104-019-4088-4
  12. American Heart Association; National Heart, Lung, and Blood Institue, Grundy SM, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev. 2005;13(6):322-327.
  13. Al-Rubean K, Youssef AM, AlFarsi Y, Al-Sharqawi AH, Bawazeer N, AlOtaibi MT, et al. Anthropometric cutoff values for predicting metabolic syndrome in a Saudi community: from the SAUDI-DM study. Ann Saudi Med. 2017;37(1):21-30. doi:10.5144/0256-4947.2017.21
  14. Scott R, Donoghoe M, Watts GF, O'Brien R, Pardy C, Taskinen MR, et al.  Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovasc Diabetol. 2011;10:102. Published 2011 Nov 21. doi:10.1186/1475-2840-10-102
  15. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5-6):231-237. doi:10.1242/dmm.001180
  16. Al-Rubeaan K, Bawazeer N, Al Farsi Y, et al. Prevalence of metabolic syndrome in Saudi Arabia - a cross sectional study. BMC Endocr Disord. 2018;18(1):16. Published 2018 Mar 5. doi:10.1186/s12902-018-0244-4
  17. Chu SY, Jung JH, Park MJ, Kim SH. Risk assessment of metabolic syndrome in adolescents using the triglyceride/high-density lipoprotein cholesterol ratio and the total cholesterol/high-density lipoprotein cholesterol ratio. Ann Pediatr Endocrinol Metab. 2019;24(1):41-48. doi:10.6065/apem.2019.24.1.41
  18. Ghodsi S, Meysamie A, Abbasi M, et al. Non-high-density lipoprotein fractions are strongly associated with the presence of metabolic syndrome independent of obesity and diabetes: a population-based study among Iranian adults. J Diabetes Metab Disord. 2017;16:25. Published 2017 Jun 7. doi:10.1186/s40200-017-0306-6
  19. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002;25(7):1135-1141. doi:10.2337/diacare.25.7.1135
  20. Vogeser M, König D, Frey I, Predel HG, Parhofer KG, Berg A. Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem. 2007;40(13-14):964-968. doi:10.1016/j.clinbiochem.2007.05.009
  21. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-2642. doi:10.1016/S0140-6736(17)32129-3
  22. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378(9785):31-40. doi:10.1016/S0140-6736(11)60679-X
  23. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-480. doi:10.1111/j.1464-5491.2006.01858.x
  24. Boden G, Chen X, DeSantis RA, Kendrick Z. Effects of age and body fat on insulin resistance in healthy men. Diabetes Care. 1993;16(5):728-733. doi:10.2337/diacare.16.5.728
  25. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163(4):427-436. doi:10.1001/archinte.163.4.427
  26. Al-Nozha MM, Abdullah M, Arafah MR, Khalil MZ, Khan NB, Al-Mazrou YY, et al. Hypertension in Saudi Arabia. Saudi Med J. 2007;28(1):77-84.
  27. Al-Rubeaan K, Al-Manaa H, Khoja T, Ahmad N, Al-Sharqawi A, Siddiqui K, et al. The Saudi Abnormal Glucose Metabolism and Diabetes Impact Study (SAUDI-DM). Ann Saudi Med. 2014;34(6):465-475. doi:10.5144/0256-4947.2014.465
  28. Reimann M, Schutte AE, Malan L, Huisman HW, Malan NT. Hyperuricaemia is an independent factor for the metabolic syndrome in a sub-Saharan African population: a factor analysis. Atherosclerosis. 2008;197(2):638-645. doi:10.1016/j.atherosclerosis.2007.09.011
  29. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57(6):845-852. doi:10.1016/j.metabol.2008.01.030
  30. Numata T, Miyatake N, Wada J, Makino H. Comparison of serum uric acid levels between Japanese with and without metabolic syndrome. Diabetes Res Clin Pract. 2008;80(1):e1-e5. doi:10.1016/j.diabres.2007.10.031
  31. Nejatinamini S, Ataie-Jafari A, Qorbani M, Nikoohemat S, Kelishadi R, Asayesh H, et al. Association between serum uric acid level and metabolic syndrome components. J Diabetes Metab Disord. 2015;14:70. Published 2015 Sep 14. doi:10.1186/s40200-015-0200-z
  32. Gonçalves JP, Oliveira A, Severo M, Santos AC, Lopes C. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine. 2012;41(3):450-457. doi:10.1007/s12020-012-9629-8
  33. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548. doi:10.1002/art.24209
  34. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752-1761. doi:10.1172/JCI21625
  35. Cheung KJ, Tzameli I, Pissios P, Rovira I, Gavrilova O, Ohtsubo T, et al. Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab. 2007;5(2):115-128. doi:10.1016/j.cmet.2007.01.005
  36. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):608-619. doi:10.1080/15257770802138558
  37. Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C, et al. Uric acid in metabolic syndrome: From an innocent bystander to a central player. Eur J Intern Med. 2016;29:3-8. doi:10.1016/j.ejim.2015.11.026
  38. Battelli MG, Bortolotti M, Polito L, Bolognesi A. The role of xanthine oxidoreductase and uric acid in metabolic syndrome. Biochim Biophys Acta Mol Basis Dis. 2018;1864(8):2557-2565. doi:10.1016/j.bbadis.2018.05.003
  39. Roumeliotis S, Roumeliotis A, Dounousi E, Eleftheriadis T, Liakopoulos V. Dietary Antioxidant Supplements and Uric Acid in Chronic Kidney Disease: A Review. Nutrients. 2019;11(8):1911. Published 2019 Aug 15. doi:10.3390/nu11081911
  40. De Pergola G, Cortese F, Termine G, Meliota G, Carbonara R, Masiello M, et al. Uric Acid, Metabolic Syndrome and Atherosclerosis: The Chicken or the Egg, Which Comes First?. Endocr Metab Immune Disord Drug Targets. 2018;18(3):251-259. doi:10.2174/1871530318666180212101548
  41. Bombelli M, Quarti-Trevano F, Tadic M, Facchetti R, Cuspidi C, Mancia G, et al. Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study. J Hypertens. 2018;36(7):1492-1498. doi:10.1097/HJH.0000000000001721
  42. King C, Lanaspa MA, Jensen T, Tolan DR, Sánchez-Lozada LG, Johnson RJ. Uric Acid as a Cause of the Metabolic Syndrome. Contrib Nephrol. 2018;192:88-102. doi:10.1159/000484283
  43. Chen LY, Zhu WH, Chen ZW, Dai HL, Ren JJ, Chen JH, et al. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B. 2007;8(8):593-598. doi:10.1631/jzus.2007.B0593
  44. Zhang Q, Zhang C, Song X, Lin H, Zhang D, Meng W, et al.  A longitudinal cohort based association study between uric acid level and metabolic syndrome in Chinese Han urban male population. BMC Public Health. 2012;12:419. Published 2012 Jun 8. doi:10.1186/1471-2458-12-419
  45. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120(5):442-447. doi:10.1016/j.amjmed.2006.06.040
  46. Matsuura F, Yamashita S, Nakamura T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism. 1998;47(8):929-933. doi:10.1016/s0026-0495(98)90346-8
  47. Westphal SA. Obesity, abdominal obesity, and insulin resistance. Clin Cornerstone. 2008;9(1):23-31. doi:10.1016/s1098-3597(08)60025-3
  48. Sun Y, Zhang H, Tian W, Shi L, Chen L, Li J, et al. Association between serum uric acid levels and coronary artery disease in different age and gender: a cross-sectional study. Aging Clin Exp Res. 2019;31(12):1783-1790. doi:10.1007/s40520-019-01137-2
  49. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-3141. doi:10.1002/art.30520
  50. Musacchio E, Perissinotto E, Sartori L, Veronese N, Punzi L, Zambon S, et al. Hyperuricemia, Cardiovascular Profile, and Comorbidity in Older Men and Women: The Pro.V.A. Study. Rejuvenation Res. 2017;20(1):42-49. doi:10.1089/rej.2016.1834
  51. Huang G, Xu JB, Zhang TJ, Nie XL, Li Q, Liu Y, et al. Hyperuricemia is associated with cardiovascular diseases clustering among very elderly women - a community based study in Chengdu, China. Sci Rep. 2017;7(1):996. Published 2017 Apr 20. doi:10.1038/s41598-017-01042-6
  52. Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone binding globulin and insulin resistance. Clin Endocrinol (Oxf). 2013;78(3):321-329. doi:10.1111/cen.12086
  53. Peng TC, Wang CC, Kao TW, Chan JY, Yang YH, Chang YW, et al. Relationship between hyperuricemia and lipid profiles in US adults. Biomed Res Int. 2015;2015:127596. doi:10.1155/2015/127596
  54. Kuwabara M, Borghi C, Cicero AFG, Hisatome I, Niwa K, Ohno M, et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. Int J Cardiol. 2018;261:183-188. doi:10.1016/j.ijcard.2018.03.045
  55. González-Chávez A, Simental-Mendía LE, Elizondo-Argueta S. Elevated triglycerides/HDL-cholesterol ratio associated with insulin resistance. Cir Cir. 2011;79(2):126-131.
  56. Salazar MR, Carbajal HA, Espeche WG, Leiva Sisnieguez CE, March CE, Balbin E, et al. Comparison of the abilities of the plasma triglyceride/high-density lipoprotein cholesterol ratio and the metabolic syndrome to identify insulin resistance. Diab Vasc Dis Res. 2013;10(4):346-352. doi:10.1177/1479164113479809
  57. Toth PP. High-density lipoprotein and cardiovascular risk. Circulation. 2004;109(15):1809-1812. doi:10.1161/01.CIR.0000126889.97626.B8
  58. Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb. 2003;10(3):186-191. doi:10.5551/jat.10.186
  59. Salazar MR, Carbajal HA, Espeche WG, Leiva Sisnieguez CE, Balbin E, Dulbecco CA, et al. Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am J Cardiol. 2012;109(12):1749-1753. doi:10.1016/j.amjcard.2012.02.016
  60. Salazar MR, Carbajal HA, Espeche WG, Aizpurua M, Leiva Sisnieguez CE, March CE, et al. Identifying cardiovascular disease risk and outcome: use of the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio versus metabolic syndrome criteria. J Intern Med. 2013;273(6):595-601. doi:10.1111/joim.12036
  61. Zurlo A, Veronese N, Giantin V, Maselli M, Zambon S, Maggi S, et al. High serum uric acid levels increase the risk of metabolic syndrome in elderly women: The PRO.V.A study. Nutr Metab Cardiovasc Dis. 2016;26(1):27-35. doi:10.1016/j.numecd.2015.10.007
  62. Cicero AFG, Fogacci F, Giovannini M, Grandi E, Rosticci M, D'Addato S, et al. Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. Sci Rep. 2018;8(1):11529. Published 2018 Aug 1. doi:10.1038/s41598-018-29955-w
  63. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707

Download Article
Received August 11, 2020.
Accepted September 17, 2020.
©2020 International Medical Research and Development Corporation.